1.
Product Overview
2.
Research Methodology
3.
Impact of COVID-19 on Olmesartan Market
4.
Executive Summary
5.
Manufacturing Olmesartan
5.1.
Raw Material
5.2.
Machinery
5.3.
Manufacturing Methods
5.4.
Contact Details of Machinery & Raw Material Suppliers
6.
Pharmacodynamic Overview of Olmesartan
6.1.
Mechanism of Action
6.2.
Absorption
6.3.
Volume of Distribution
6.4.
Protein Binding
6.5.
Metabolism
6.6.
Route of Elimination
6.7.
Half-Life
6.8.
Clearance
6.9.
Toxicity
7.
India Olmesartan Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value &
Volume
7.2.
Market Share & Forecast
7.2.1. By Dose (10 mg, 20
mg, 40 mg, Others)
7.2.2. By Source (In-house
v/s Contract Manufacturing Organizations)
7.2.3. By Distribution
Channel (Online v/s Offline)
7.2.4. By Application (High
Blood Pressure, Heart Failure, Diabetic Kidney Disease Others)
7.2.5. By End User (Adult
v/s Paediatric)
7.2.6. By Region (North,
East, South, West)
7.2.7. By Company
7.3.
Product Market Map
8.
Market Dynamics
8.1.
Drivers/Opportunities
8.2.
Challenges/Restraints
9.
Market Trends & Developments
10.
Policy & Regulatory Landscape
10.1.
Custom Duty & Taxes
10.2.
Government Subsidy & Benefits
10.3.
Relevant Policies & Regulations (GMP, USFDA, WHO Certifications)
11.
Import & Export Analysis
12.
Pricing Analysis
13.
India Economic Profile
14.
Competitive Landscape
14.1.
Company Profiles
14.1.1. Glenmark
Pharmaceuticals Ltd.
14.1.1.1. Company Brief
14.1.1.2. Production Plants
& Capacity (If Available)
14.1.1.3. Financials (If
Available)
14.1.1.4. Captive Consumption
Vs Merchant Sale
14.1.1.5. Current & Future
Plans
14.1.2. Alembic
Pharmaceuticals Ltd.
14.1.3. Cadila
Pharmaceuticals Ltd.
14.1.4. Sun Pharmaceuticals
Industries Ltd.
14.1.5. Unichem Laboratories
Ltd.
14.1.6. Cipla Ltd.
14.1.7. Torrent Pharmaceuticals
Ltd.
14.1.8. Lupin Laboratories
Ltd. (Pinnacle)
14.1.9. Abbott Healthcare
Pvt. Ltd.
14.1.10. Morepen Laboratories Ltd.
15.
Strategic Recommendations
About Us &
Disclaimer